ClinicalTrials.gg
RecruitingNCT06468098Updated Jul 18, 2024

A Study of IBI363 in Subjects With Advanced Malignancies

A Phase 1 interventional study of IBI363 + chemotherapy and IBI363 + Investigator's Choice SOC in Advanced Malignancies, sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-18.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
556
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is an open-label, multicenter Phase Ib study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced malignancies patients

02

Conditions studied

  • Advanced Malignancies
03

In context

Lead sponsor

Innovent Biologics (Suzhou) Co. Ltd. is the lead sponsor of 199 studies on the registry; 46 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign written and be able to comply with the program's visit schedule and related procedures.
  2. Male or female subjects, age 18\~75 years.
  3. or cytologically confirmed advanced .
  4. Subjects who have progressed on standard therapy, who are unsuitable for standard therapy, who do not have standard therapy, or who have refused standard therapy. For particular cohort, subjects who have not received prior systemic therapy for advanced disease.
  5. At least one (target lesion) per v1.1.
  6. Performance Status (ECOG PS) of 0 or 1.
  7. of 3 months or more.
  8. Female subjects of childbearing age or male subjects whose partners are female subjects of childbearing age agree to strictly adopt effective measures throughout the entire treatment period and 6 months after the treatment period.

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant or lactating, or intending to become pregnant before, during, or within 6 months after the last dose of study drug.
  2. Active or untreated confirmed by imaging evaluation during screening or previous imaging evaluation. Patients with asymptomatic brain metastases may participate in this study.
  3. History of active thrombosis or deep vein thrombosis or pulmonary embolism within 4 weeks prior to the first dose of study drug.
  4. cardiovascular or cerebrovascular disease.
  5. Interstitial pneumonia, pulmonary fibrosis, pneumoconiosis, drug-associated pneumonia, and radiation pneumonitis requiring hormone or other therapy, as well as history of severe abnormal lung function or other forms of restrictive lung disease.
  6. History of allergies, asthma, atopic dermatitis.
  7. Concomitant pleural or pericardial effusion requiring repeated drainage or with significant symptoms.
  8. Active disease requiring systemic therapy within 2 years prior to first dose.
  9. Known history of allogeneic organ transplantation and hematopoietic stem cell transplantation.
  10. Subjects with known or suspected to the study drug and any .
  11. Subject has a prior history of significant toxicity associated with administration that requires permanent discontinuation.
  12. Subjects with unresolved > Grade 1 toxicity associated with any prior antineoplastic therapy, with the exception of persistent Grade 2 alopecia, peripheral neuropathy, hypomagnesemia, and toxicities that are not expected to be reversible but are stably controlled by medications (e.g., hypothyroidism stably controlled by substitution therapy, hypertension stably controlled by antihypertensive medications with a BP of less than 160/100 mmHg).
  13. Inadequate recovery from previous surgery or any major surgery within 4 weeks prior to the first dose of study drug.
  14. Active uncontrolled bleeding or known bleeding tendency.
  15. Subject has a current or recent (within 6 months) major gastrointestinal disease or condition.
  16. Subjects with uncontrolled tumor-related pain or symptomatic hypercalcemia.
  17. Known positive test, active , (HCV), tuberculosis.
  18. Severe/active/uncontrolled infection, infection requiring systemic intravenous antibiotic therapy, or unexplained fever within 2 weeks prior to the first dose of study drug.
  19. Diagnosis of another within 5 years prior to the first dose, exceptions include radically treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or radically resected carcinoma in situ, as well as post-radical localized prostate cancer, and papillary thyroid cancer.
  20. Exclusion of to combination medications including, but not limited to: known contraindications to irinotecan therapy for the combination irinotecan or liposomal irinotecan cohort including, but not limited to: having the UGTA1*6/*6, UGT1A1*28/*28, or UGT1A1*6/*28 genotypes; history of prior pelvic and abdominal radiotherapy.
  21. Presence of any disease, treatment or laboratory test abnormality, or history or current evidence of substance abuse that, in the judgment of the investigator, may compromise the safety of the subject, interfere with obtaining , affect subject compliance, or compromise the safety evaluation of the study drug.
  22. Mental illness, presence of altered mental status, or substance abuse that prevents understanding of the informed consent process and/or completion of necessary study-related evaluations.
  23. For known or foreseeable reasons, the Investigator believes that the subject is unable to fulfill the requirements of the protocol.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
556 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    IBI363 combined with chemotherapy in patients with advanced NSCLC who have failed at least one prior line of standard therapy (which needs to include immunotherapy)

    Drug: IBI363 + chemotherapy

  • Experimental
    Cohort 2A

    IBI363 combined with chemotherapy as first-line in patients with advanced colorectal cancer, including a safety run-in phase and a randomized controlled phase

    Drug: IBI363 + chemotherapy

  • Experimental
    Cohort 2B

    IBI363 combined with chemotherapy as first-line in patients with advanced colorectal cancer, including a safety run-in phase and a randomized controlled phase

    Drug: IBI363 + chemotherapy

  • Experimental
    Cohort 3

    IBI363 combined with chemotherapy in patients with advanced biliary tract tumors that have failed or are intolerant to first-line standard therapy

    Drug: IBI363 + chemotherapy

  • Experimental
    Cohort 4

    IBI363 combined with chemotherapy in second-line in patients with Advanced Esophageal Squamous Cell Carcinoma

    Drug: IBI363 + chemotherapy

  • Experimental
    Cohort 5

    IBI363 combined with chemotherapy in second-line in patients with Advanced Gastric Cancer

    Drug: IBI363 + chemotherapy

  • Experimental
    Cohort 6

    IBI363 combined with chemotherapy in patients with Advanced Triple-Negative Breast Cancer

    Drug: IBI363 + chemotherapy

  • Experimental
    Cohort 7

    IBI363 combined with chemotherapy in patients with platinum-resistant ovarian cancer that has failed or is intolerant to standard therapy

    Drug: IBI363 + chemotherapy

  • Experimental
    Cohort 8

    IBI363 Combined with Investigator's Choice Standard of Care(SOC) in Patients with Advanced Solid Tumors

    Drug: IBI363 + Investigator's Choice SOC

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Enent (AE)

    Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0

    Time frame: Up to 90 days after the last administration

  2. Treatment-Emergent AE (TEAE)

    Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0

    Time frame: Up to 90 days after the last administration

  3. Adverse Event of Special Interest (AESI)

    Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0

    Time frame: Up to 90 days after the last administration

  4. Serious Adverse Event (SAE)

    Adverse events will be assessed by investigator(s) according to NCI-CTCAE v5.0

    Time frame: Up to 90 days after the last administration

  5. Objective response rate (ORR)

    ORR is defined as the proportion of participants with a complete response (CR) or partial response (PR).

    Time frame: Through out the study (up to 2 years)

  6. disease control rate (DCR)

    DCR is defined as the proportion of participants with a complete response (CR) or partial response (PR) or stable disease(SD)

    Time frame: Through out the study (up to 2 years)

  7. time to response (TTR)

    TTR is defined as the time from the date of first dose of study drug to the date of first documented tumor response (CR/PR)

    Time frame: Through out the study (up to 2 years)

  8. duration of response (DoR)

    DoR is defined as the time from the date of first documented tumor response (CR/PR) until PD/death

    Time frame: Through out the study (up to 2 years)

  9. progression-free survival (PFS)

    PFS is defined as the time from the date of first dose of study drug to the date of the first documented progression or death due to any cause, whichever occurs first

    Time frame: Through out the study (up to 2 years)

  10. Overall survival (OS)

    OS is defined as the time from the date of first dose of study drug until the date of death from any cause.

    Time frame: Through out the study (an average of 2 years)

Secondary outcomes

  1. Plasma concentration (Cmax) of IBI363

    PK parameters maximum concentration (Cmax) of IBI363

    Time frame: Up to 2 years

  2. Area under the curve (AUC) of IBI363

    PK parameters area under the curve (AUC)?of IBI363

    Time frame: Up to 2 years

  3. Half-life (T1/2) of IBI363

    PK parameters half-life (t1/2)?of IBI363

    Time frame: Up to 2 years

  4. Clearance (CL) of IBI363

    PK parameters clearance rate of IBI363

    Time frame: Up to 2 years

  5. Volume of distribution (V) of IBI363

    PK parameters apparent volume of distribution(V)?of IBI363

    Time frame: Up to 2 years

  6. Immunogenicity of IBI363

    Incidence of anti-drug (IBI363) antibody

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
  • Shanghai Chest Hospita
    Shanghai, Shanghai Municipality 20030, China
    Recruiting
    • shun Lu · Contactshunlu_shchest@sina.com · 021-22200000
    • hongxia Lu, M.D. · Principal investigator
    • guiying Wang, M.D. · Principal investigator
    • yifu He, M.D. · Principal investigator
    • lifeng Wang, M.D. · Principal investigator
    • dingzhi Huang, M.D. · Principal investigator
    • xiaobing Chen, M.D. · Principal investigator
    • yong Li, M.D. · Principal investigator
    • jianwei Yang, M.D. · Principal investigator
    • zhiwei Li, M.D. · Principal investigator
    • haibo Zhu, M.D. · Principal investigator
    • haijun Zhong, M.D. · Principal investigator
    • zuoxing Niu, M.D. · Principal investigator
    • runxiang Yang, M.D. · Principal investigator
    • qiming Wang, M.D. · Principal investigator
    • haohui Fang, M.D. · Principal investigator
    • leilei Yuan, M.D. · Principal investigator
    • zhentian Liu, M.D. · Principal investigator
    • yuping Sun, M.D. · Principal investigator
    • yongchang Zhang, M.D. · Principal investigator
    • yifen Wu, M.D. · Principal investigator
    • ruinian Zheng, M.D. · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Jun 2025, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2024
First posted
Jun 21, 2024
StartActual
Jun 15, 2024
Primary completionEst.
Jun 30, 2025
CompletionEst.
Dec 31, 2026
Last update
Jul 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06468098
Responsible party
Sponsor
First posted
Jun 21, 2024
Start date
Jun 15, 2024
Primary completion
Jun 30, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 18, 2024

Study contacts

binbin Min
Contact
bingo.min@innoventbio.com
0512-69566088
tingbo Liang, M.D.
principal investigator · The First Affiliated Hospital ZJ University
xueli Bai, M.D.
principal investigator · The First Affiliated Hospital ZJ University
jianming Xu, M.D.
principal investigator · Chinese PLA General Hospital
shun Lu, M.D.
principal investigator · Shanghai Chest Hospita
tao Zhang, M.D.
principal investigator · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363

Start the discussion